Anton Vladić

1.0k total citations
26 papers, 726 citations indexed

About

Anton Vladić is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Anton Vladić has authored 26 papers receiving a total of 726 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 8 papers in Oncology and 8 papers in Immunology. Recurrent topics in Anton Vladić's work include Multiple Sclerosis Research Studies (12 papers), Immunotherapy and Immune Responses (5 papers) and Systemic Lupus Erythematosus Research (3 papers). Anton Vladić is often cited by papers focused on Multiple Sclerosis Research Studies (12 papers), Immunotherapy and Immune Responses (5 papers) and Systemic Lupus Erythematosus Research (3 papers). Anton Vladić collaborates with scholars based in Croatia, Czechia and Italy. Anton Vladić's co-authors include David Margolin, Vesna Brinar, Edward Fox, Alasdair Coles, Marijan Klarica, Jeffrey Palmer, Krzysztof Selmaj, Ann Bass, Stephen Lake and Susan Moran and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Neurology and The Lancet Neurology.

In The Last Decade

Anton Vladić

25 papers receiving 694 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anton Vladić Croatia 12 452 218 199 190 141 26 726
Verena I. Leussink Germany 14 331 0.7× 229 1.1× 162 0.8× 106 0.6× 76 0.5× 20 591
Marc Coustans France 10 689 1.5× 338 1.6× 98 0.5× 249 1.3× 197 1.4× 10 878
T. Arbizu Spain 15 563 1.2× 216 1.0× 154 0.8× 161 0.8× 165 1.2× 28 745
Peter Huppke Germany 20 756 1.7× 491 2.3× 127 0.6× 160 0.8× 218 1.5× 39 1.1k
P. O’Connor Canada 10 783 1.7× 221 1.0× 233 1.2× 242 1.3× 152 1.1× 16 1.0k
Yuichi Kawata Japan 8 616 1.4× 568 2.6× 171 0.9× 53 0.3× 178 1.3× 21 873
Gillian Ingram United Kingdom 18 964 2.1× 346 1.6× 388 1.9× 185 1.0× 299 2.1× 38 1.3k
Bruno Brochet France 6 735 1.6× 398 1.8× 55 0.3× 105 0.6× 190 1.3× 12 872
Ann Dring United Kingdom 15 277 0.6× 296 1.4× 113 0.6× 151 0.8× 53 0.4× 17 865
Aaron E. Miller United States 10 381 0.8× 145 0.7× 151 0.8× 117 0.6× 111 0.8× 18 656

Countries citing papers authored by Anton Vladić

Since Specialization
Citations

This map shows the geographic impact of Anton Vladić's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anton Vladić with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anton Vladić more than expected).

Fields of papers citing papers by Anton Vladić

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anton Vladić. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anton Vladić. The network helps show where Anton Vladić may publish in the future.

Co-authorship network of co-authors of Anton Vladić

This figure shows the co-authorship network connecting the top 25 collaborators of Anton Vladić. A scholar is included among the top collaborators of Anton Vladić based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anton Vladić. Anton Vladić is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rolla, Simona, Stefania Federica De Mercanti, Valentina Bardina, et al.. (2022). Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up. Frontiers in Immunology. 13. 818325–818325. 8 indexed citations
2.
Selmaj, Krzysztof, Mario Habek, Ann Bass, et al.. (2017). Efficacy and Safety of Alemtuzumab in Patients With RRMS Is Durable Over 10 Years: Follow-up From the CAMMS223 Study (P5.338). Neurology. 88(16_supplement). 6 indexed citations
3.
Durelli, Luca, Simona Rolla, Stefania De Mercanti, et al.. (2017). A four year immunological study of responsive and non responsive MS patients after alemtuzumab to search for indications of retreatment (P5.398). Neurology. 88(16_supplement). 1 indexed citations
4.
Rolla, Simona, Stefania Federica De Mercanti, Valentina Bardina, et al.. (2017). Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. Journal of Neuroimmunology. 313. 89–91. 8 indexed citations
5.
Mercanti, Stefania De, Simona Rolla, Valentina Bardina, et al.. (2016). Alemtuzumab long-term immunologic effect. Neurology Neuroimmunology & Neuroinflammation. 3(1). e194–e194. 54 indexed citations
6.
Petlevski, Roberta, et al.. (2014). Progression of multiple sclerosis is associated with gender differences in glutathione S-transferase P1 detoxification pathway. Repository of the Medical Faculty of the University of Zagreb (University of Zagreb). 1 indexed citations
7.
Petlevski, Roberta, et al.. (2014). Progression of multiple sclerosis is associated with gender differences in glutathione S-transferase P1 detoxification pathway. Acta Neurobiologiae Experimentalis. 74(3). 257–265. 9 indexed citations
8.
Daniels, Gilbert H., Anton Vladić, Vesna Brinar, et al.. (2013). Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis. The Journal of Clinical Endocrinology & Metabolism. 99(1). 80–89. 111 indexed citations
9.
Fox, Edward, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up (S41.001). Neurology. 80(7_supplement). 11 indexed citations
10.
Klarica, Marijan, et al.. (2013). “Compensated hyperosmolarity” of cerebrospinal fluid and the development of hydrocephalus. Neuroscience. 248. 278–289. 39 indexed citations
11.
Mercanti, Stefania De, Marinella Clerico, Simona Rolla, et al.. (2013). Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: A 24 Months Immunological Study (P05.148). Neurology. 80(7_supplement). 1 indexed citations
12.
Coles, Alasdair, Edward Fox, Anton Vladić, et al.. (2012). Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial. Neurology. 78(14). 1069–1078. 193 indexed citations
13.
Mercanti, Stefania De, Daniela Taverna, Simona Rolla, et al.. (2012). T Regulatories (Tregs) and Suppressor Cytokine mRNA (IL-10, TGF , IL-27) Increase after Alemtuzumab in MS: First 24 Month Immunological Report on 323 and 324 Genzyme Trials (P02.088). Neurology. 78(Meeting Abstracts 1). P02.088–P02.088. 1 indexed citations
14.
Coles, Alasdair, Edward Fox, Anton Vladić, et al.. (2011). Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. The Lancet Neurology. 10(4). 338–348. 101 indexed citations
15.
Budinčević, Hrvoje, et al.. (2010). Quality of life in multiple sclerosis patients.. 2 indexed citations
16.
Vladić, Anton, Marijan Klarica, & Marin Bulat. (2008). Dynamics of distribution of 3H-inulin between the cerebrospinal fluid compartments. Brain Research. 1248. 127–135. 20 indexed citations
17.
Filić, Vedrana, Anton Vladić, Jasminka Štefulj, et al.. (2004). Monoamine oxidases A and B gene polymorphisms in migraine patients. Journal of the Neurological Sciences. 228(2). 149–153. 33 indexed citations
18.
Jernej, Branimir, Anton Vladić, Lipa Čičin‐Šain, et al.. (2002). Platelet Serotonin Measures in Migraine. Headache The Journal of Head and Face Pain. 42(7). 588–595. 19 indexed citations
19.
20.
Vladić, Anton, et al.. (2000). Homeostatic role of the active transport in elimination of [3H]benzylpenicillin out of the cerebrospinal fluid system. Life Sciences. 67(19). 2375–2385. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Verena I. Leussink Breakdown of academic impact, for papers by Marc Coustans Breakdown of academic impact, for papers by T. Arbizu Breakdown of academic impact, for papers by Peter Huppke Breakdown of academic impact, for papers by P. O’Connor Breakdown of academic impact, for papers by Yuichi Kawata Breakdown of academic impact, for papers by Gillian Ingram Breakdown of academic impact, for papers by Bruno Brochet Breakdown of academic impact, for papers by Ann Dring Breakdown of academic impact, for papers by Aaron E. Miller
Rankless by CCL
2026